Neuroprotective treatment for Parkinson’s disease

References

• Reich SG, Lederman MB, Griswold ME. Errors and delays in diagnosing Parkinson's disease. Ann. Neural. 52, S84 (2002).
   Google Scholar
• Tipton KF, Singer TE Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61,1191–1206 (1993).
   PubMed Web of Science ®Google Scholar
• McCormack AL, Thiruchelvam M, Manning-Bog AB eta! Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neumbial Dis. 10,119–127 (2002).
   PubMed Web of Science ®Google Scholar
• Menegon A, Board PG, Blackburn AC et al Parkinson's disease, pesticides and glutathione transferase polymorphisms. Lancet352, 1344–1346 (1998).
   PubMed Web of Science ®Google Scholar
• Butterfield PG, Valanis BG, Spencer PS et al Environmental antecedents of young-onset Parkinson's disease. Neumlogy43, 1150–1158 (1993).
   PubMed Web of Science ®Google Scholar
• Gorell JM, Johnson CC, Rybicki BA etal. The risk of Parkinson's disease with exposure to pesticides, farming, well water and rural living. Neurology50, 1346–1350 (1998).
   Google Scholar
• Engel LS, Checkoway H, Keifer MC eta]. Parkinsonism and occupational exposure to pesticides. Occup. Environ. Merl 58, 582–589 (2001).
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, MacKenzie G. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Aiwusci. 3, 1301–1306 (2000).
   Google Scholar
• Hicks AA, Petursson H, Jonsson T A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. New& 52, 549–555 (2002).
   Google Scholar
• Maruyama W, Akao Y, Carrillo MC eta! Neuroprotection by propargylamines in Parkinson's disease. Suppression of apoptosis and induction of prosurvival genes. Neurotox. 7eratol 24, 675–682 (2002).
   Google Scholar
• Parkinson Study Group. A controlled trialof rasagiline in early Parkinson's disease: the TEMPO study. Arch. Neural 59, 1937–1943 (2002).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann. Neural. 40, 99–107 (1996).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Cooper JM, Dexter D eta]. Mitochondrial complex I deficiency in Parkinson's disease. J. Neumchem. 54, 823–827 (1990).
   Google Scholar
• Shults CW, Oakes D, Kieburtz K eta]. Effects of coenzyme Q10 in early Parkinson's disease. Arch. Neural. 59, 1541–1550 (2002).
   Google Scholar
• Rosenberg RN. Mitochondrial therapy for Parkinson's disease. Arch. Neural. 59, 1523 (2002).
   PubMedGoogle Scholar
• Beal ME. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann.
   Google Scholar
• (Suppl. 3), S39—S48 (2003). Review of experimental and clinical evidence that impaired mitochondrial function, oxidative damage, and inflammation contribute to the pathogenesis of Parkinson's disease.
   Google Scholar
• Jankovic J, Hunter C. A double-blind, placebo- controlled and longitudinal study of riluzole in early Parkinsoris disease. Par/citron/2n Relat. Distr./. 8, 271–276 (2002).
   Google Scholar
• Rascol 0, Olanow CW, Brooks D eta]. A 2-year, multicenter, placebo-controlled, double-blind, parallel group study of the effect of riluzole on Parkinson's disease progression. Mov. Disord. 17\(Suppl. 5), S39 (2002).
   Google Scholar
• Beal ME. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neural. 44, S110—S114 (1998). 20Du Y, Ma Z, Lin S eta! Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sc]. 98, 14669–14674 (2001).
   Google Scholar
• Bruet N, Windels F, Bertrand A eta]. High frequency stimulation of the subthalamic nucleus increases the extracellular contents of striatal dopamine in normal and partially dopaminergic denervated rats. Neuropathol Exp. Neural. 60, 15–24 (2001).
   Google Scholar
• Luo J, Kaplitt MG, Fitzsimons HL et alSubthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298, 425–429 (2002).
   PubMed Web of Science ®Google Scholar
• Kreiss DS, Mastropietro CW, Rawji SS, Walters JR. The response of subthalamic nucleus to dopamine receptor stimulation in a rodent model of Parkinson's disease. J. Neurosci. 17, 6807–6819 (1997).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Neurology54, 1583–1588 (2000).
   PubMed Web of Science ®Google Scholar
• McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson's disease. Adv. Neural. 86, 83–89 (2001).
   Google Scholar
• Langston JW, Porno LS, Tetrud J et al Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Nemo'. 46, 598–605 (1999).
   Google Scholar
• Kurkowska-Jastrzebska I, Wronska A,Kohutnicka M et al The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp. Neural. 156, 50–61 (1999).
   Google Scholar
• Wu DC, Jackson-Lewis V, Vila M eta]. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neumsci. 22, 1763–1771 (2002).
   Google Scholar
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
   Google Scholar
• Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39, 167–174 (2001).
   PubMed Web of Science ®Google Scholar
• Liu B, Gao HM, Wang JY eta! Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. NY Acad. Sc]. 962, 318–331 (2002).
   PubMed Web of Science ®Google Scholar
• Fahn S. Parkinson& apos;s disease, the effect of levodopa and the ELLDOPA trial. Arch. Neural 56, 529–535 (1999).
   PubMed Web of Science ®Google Scholar
• Agid Y. Levodopa: is toxicity a myth? Neurology50, 858–863 (1998).
   PubMed Web of Science ®Google Scholar
• Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/ cortical astrocyte cocultures. j Neurochem. 69, 1398–1408 (1997).
   Google Scholar
• Murer MG, Dziewczapolski G, Menalled LB eta! Chronic levodopa is not toxic for remaining dopamine neurons but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neural 43, 561–575 (1998).
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Kosaka T, Kakimura JI eta! Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mal. Pharmacol 54,1046–1054 (1998).
   Google Scholar
• Linazasoro GL. Neuroprotection inParkinson's disease: love story or mission impossible? Expert Rev Neurotherapeutics2, 403–416 (2002).
   PubMedGoogle Scholar
• Morrish, P Is it time to abandon functional imaging in the study of neuroprotection? Mori. Disairl. 17, 229–232 (2002).
   PubMed Web of Science ®Google Scholar
• Guttman M, Stewart D, Hussey D et al Influence of L-DOPA and pramipexole on striatal dopamine transporter in early PD. Neurology56, 1559–1564 (2001).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson's disease progression. JAMA 287, 1653–1661 (2002).
   Google Scholar
• Grondin R, Zhang Z, Yi A eta! Chronic controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125, 2191–2201 (2002).
   PubMed Web of Science ®Google Scholar
• ••Glial-derived neurotrophic factor (GDNF)infused into the striatum and lateral ventricle of a monkey-model of Parkinson's disease led to functional improvement accompanied by upregulation and regeneration of nigral dopaminergic neurons.
   Google Scholar
• Brundin P GDNF treatment in Parkinson's disease: time for controlled clinical trials? Brain 125, 2149–2151 (2002).
   PubMed Web of Science ®Google Scholar
• Shingo T, Date I, Yoshida H, Ohmoto T Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson's disease. J. Neurosci. Res. 69, 946–954 (2002).
   PubMed Web of Science ®Google Scholar
• Kordower JH, Palfi S, Chen EY eta! Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neural 46, 419–424 (1999).
   PubMed Web of Science ®Google Scholar
• Gill SS, Patel NK, Hotton GR et al Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nature Merl 9, 589–595 (2003).
   PubMed Web of Science ®Google Scholar
• ••GDNF delivered into the putamen of fivepatients was without serious side-effects and led to symptomatic benefit.
   Google Scholar
• Emborg ME, Shin P, Roitberg B et al Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp. Ai'lliVi 168, 171–182 (2001).
   Google Scholar
• Eberling JL, Pivirotto P, Bringas J et al The immunophilin ligand GOI-1046 does not have neuroregenerative effects in MPTP-treated monkeys. Exp. Neural 178, 236–242 (2002).
   Google Scholar
• Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. Pharmacol Exp. Ther. 288, 421–427 (1999).
   Google Scholar
• Kieburtz K. Designing neuroprotection trials in Parkinson's disease. Ann. Neural 53\(Suppl. 3), S100—S109 (2003).
   Google Scholar
• •Reviews approaches to the design of clinical trials to assess neuroprotective treatments.
   Google Scholar
• Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann. New& 53\(Suppl. 3), S87—S99 (2003). Reviews some of the earlier clinical trials of possible protective agents, with discussion of some of the difficulties in designing and interpreting such trials.
   Google Scholar